ArticleCancers2022

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

Mihály Cserepes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.